Research programme: HSC derived CAR engineered invariant natural killer T cells therapies - Appia Bio/Kite Pharma
Alternative Names: Haematopoietic stem cells derived CAR-iNKT cell therapies - Appia Bio/Kite Pharma; HSC-derived CAR-iNKT cell therapies - Appia Bio/Kite PharmaLatest Information Update: 28 Sep 2023
At a glance
- Originator Appia Bio; Kite Pharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Haematopoietic stem cells therapies; Immunotherapies; NKT cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural Killer T-cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies
- Research Solid tumours
Most Recent Events
- 28 Sep 2023 Preclinical trials in Haematological malignancies in USA (Parenteral) (Appia Bio pipeline; September 2023)
- 24 Aug 2021 Appia Bio and Kite Pharma enters into collaboration and license agreement for research and development of HSC-derived cell therapies for the treatment of haematological malignancies
- 24 Aug 2021 Early research in Haematological malignancies in USA (Parenteral)